Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Pharvaris, with a price target of $52.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Debanjana Chatterjee has given his Buy rating due to a combination of factors tied to Pharvaris’ lead asset deucrictibant and its late-stage pipeline in hereditary angioedema. He expects the Phase 3 CHAPTER-3 long-term prophylaxis study of the extended-release formulation to deliver robust efficacy versus placebo in 3Q26, with attack reduction that should rival injectable competitors and surpass the currently approved oral option.
Chatterjee’s positive stance is further supported by strong Phase 3 data for the immediate-release formulation in on-demand treatment, which he believes positions it well for regulatory approval and substantial market uptake alongside, and at the expense of, existing therapies. He also highlights the company’s solid cash runway into the first half of 2027 and upwardly revised revenue and peak penetration forecasts, which together justify increasing the DCF-based price target to $52 and maintaining a Buy recommendation.
Chatterjee covers the Healthcare sector, focusing on stocks such as Tvardi Therapeutics, Spyre Therapeutics, and Intellia Therapeutics. According to TipRanks, Chatterjee has an average return of 43.0% and a 61.59% success rate on recommended stocks.
In another report released on April 8, Morgan Stanley also maintained a Buy rating on the stock with a $41.00 price target.